Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Vertex Pharmaceuticals stock was among the worst performer in the S&P 500 index early Tuesday after the drugmaker said it ...

Stock futures were rising early Tuesday as markets continued to gain on the back of improving odds for a September rate ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...

Vertex Pharmaceuticals Inc. shares fell 15% after an experimental pain drug failed to benefit patients after surgery and US ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.15% to $462.13 Friday, on what proved to be an all-around grim trading ...

Google's Veo 3 and Veo 3 Fast AI video generators are both available in Vertex AI, giving users access to a new model ...